Pharming announces EU12.0 million private equity placement with institutional investors

LEIDEN, Netherlands, Oct. 9, 2013 (GLOBE NEWSWIRE) --

Biotech  company Pharming  Group NV
("Pharming" or "the Company") (NYSE Euronext: PHARM) today announced that it has
entered  into a  private equity  placement of  €12.0 million  (€11.5 million net
proceeds   after   subtraction  of  transaction  fees)  with  existing  and  new
institutional  investors. Participating institutional  investors include current
shareholders  Deerfield  Management  Company,  Kingdon  Capital  Management  and
Broadfin Capital.

The  placement is priced at €0.117 per share, which represents a 10% discount to
last  night's closing  price of  €0.13 per  share. A total of 102,564,103 shares
will  be  issued  to  the  investors.  In  addition  the  investors will receive
25,641,026 Warrants  with a strike  price of €0.135.  The exercise period of the
warrants is five years.

Sijmen  de Vries, Pharming CEO, said: "I am pleased that, ahead of the April FDA
decision  on  the  Ruconest®  BLA,  our existing institutional shareholders have
demonstrated  their belief in  the potential of  the Company by increasing their
holding.  I am  also pleased  to note  that new  institutional shareholders have
decided  to  also  take  a  position  in  our  Company.  This  private placement
represents  an important  strengthening of  our balance  sheet, not only does it
allow  us to  continue to  fund the  manufacturing of  new Ruconest inventory in
preparation  for a US launch and roll-out, it also allows us to fund the planned
US  clinical trial for prophylaxis of HAE together with our US partner Santarus,

After  completion  of  this  transaction  the  number of outstanding shares will
increased  from 229,870,216 to 332,434,319. The  new shares will  be admitted to
listing and trading on Euronext Amsterdam pursuant to a listing prospectus which
is expected to be published next week upon AFM approval on the Company's website
and on the AFM website.

Roth  Capital Partners  acted as  the lead  placement agent  to Pharming in this

                            About Pharming Group NV

Pharming  Group NV is developing innovative  products for the treatment of unmet
medical  needs. RUCONEST®  (conestat alfa)  is a  recombinant human  C1 esterase
inhibitor  approved for the treatment of angioedema attacks in patients with HAE
in   all  27 EU  countries  plus  Norway,  Iceland  and  Liechtenstein,  and  is
distributed  in the EU by Swedish  Orphan Biovitrum. RUCONEST® is partnered with
Santarus,  Inc.  (NASDAQ:  SNTS)  in  North  America  and  a  Biologics  License
Application  (BLA)  for  RUCONEST®  is  under  review  by the U.S. Food and Drug
Administration.  The  product  is  also  being  evaluated  for various follow-on
indications.  Pharming has  a unique  GMP compliant,  validated platform for the
production  of recombinant human  proteins that has  proven capable of producing
industrial  volumes  of  high  quality  recombinant  human  protein  in  a  more
economical  way compared to  current cell based  technologies. In July 2013, the
Platform  was  partnered  with  Shanghai  Institute  for Pharmaceutical Industry
(SIPI),  a Sinopharm Company, for joint global development of new products. Pre-
clinical development and manufacturing will take place at SIPI and are funded by
SIPI.  Pharming  and  SIPI  initially  plan  to  utilise  this  platform for the
development   of   rhFVIII  for  the  treatment  of  Haemophilia  A.  Additional
information is available on the Pharming website,

Additional information is available on the Pharming website,

This  press release contains  forward looking statements  that involve known and
unknown  risks,  uncertainties  and  other  factors,  which may cause the actual
results,  performance or achievements of the  Company to be materially different
from  the results,  performance or  achievements expressed  or implied  by these
forward looking statements.


Pharming :
Sijmen de Vries, CEO: T: +31 71 524 7400

FTI Consulting :
Julia Phillips/ John Dineen, T: +44 (0)207 269 7193

Press release (PDF):